Top

Published in:

01-04-2012 | Original Communication

Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy

Authors: Atsushi Hashizume, Masahisa Katsuno, Haruhiko Banno, Keisuke Suzuki, Noriaki Suga, Fumiaki Tanaka, Gen Sobue

Published in: Journal of Neurology | Issue 4/2012

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an adult-onset, X-linked motor neuron disease characterized by muscle atrophy, weakness, and bulbar involvement. The aim of this study was to analyze the differential change of various outcome measures by comparing the progression of motor impairment in the two independent groups: placebo-treated group (PTG) and natural history group (NHG). For the PTG, we analyzed 99 patients who participated in a previous double-blind phase III clinical trial and received placebo. For the NHG, a total of 34 patients were followed with no specific treatment. The characteristics of both groups did not differ at baseline except for disease duration. Although the 6 min walk distance (6MWD) showed almost the same progression in both groups (−14.7 ± 7.3 m in NHG, −14.0 ± 4.7 m in PTG; NS), there was a significant difference of progression in the ALSFRS-R between the NHG and PTG (−1.18 ± 0.38, −0.14 ± 0.24; p = 0.03). A similar tendency was also seen in the subgroup analysis of the patients whose disease durations were less than 10 years. Although the relationship between the ALSFRS-R and 6MWD at week 48 was similar to that at baseline in the NHG, the slope of the regression at week 48 was significantly milder than at baseline in the PTG (p = 0.04). In conclusion, these two groups demonstrated a large difference in the chronological analysis of a motor function score, but showed similar changes in objective measures of walking capacity. These findings should be thoroughly considered when designing clinical trials for slowly progressive neurodegenerative diseases such as SBMA.

Available only for authorised users

Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18:671–680PubMed

Sperfeld AD, Karitzky J, Brummer D et al (2002) X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 59:1921–1926PubMedCrossRef

Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209–232PubMedCrossRef

Atsuta N, Watanabe H, Ito M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(Pt 6):1446–1455PubMedCrossRef

La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79PubMedCrossRef

Fischbeck KH (1997) Kennedy disease. J Inherit Metab Dis 20:152–158PubMedCrossRef

La Spada AR, Taylor JP (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11:247–258PubMedCrossRef

Sobue G, Doyu M, Kachi T et al (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117:74–78PubMedCrossRef

Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770–772PubMed

10.

Katsuno M, Adachi H, Kume A et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843–854PubMedCrossRef

11.

Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768–773PubMedCrossRef

12.

Takeyama K, Ito S, Yamamoto A et al (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855–864PubMedCrossRef

13.

Chevalier-Larsen ES, O’Brien CJ, Wang H et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24:4778–4786PubMedCrossRef

14.

Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520–526PubMedCrossRef

15.

Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140–150PubMedCrossRef

16.

Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875–884PubMedCrossRef

17.

Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602PubMedCrossRef

18.

Diederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677–684PubMedCrossRef

19.

The ALS (1996) CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141–147CrossRef

20.

Ohashi Y, Tashiro K, Itoyama Y et al (2001) Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei 53:346–355PubMed

21.

Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M (1999) Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol 246(Suppl 3):III16–III21PubMedCrossRef

22.

Jenkinson C, Fitzpatrick R (2001) Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 70:70–73PubMedCrossRef

23.

Yamaguchi T, Ohbu S, Saito M et al (2004) Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis–assessment questionnaire 40 (ALSAQ-40). No To Shinkei 56:483–494PubMed

24.

Besinger UA, Toyka KV, Hömberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316–1321PubMed

25.

Takeuchi Y, Katsuno M, Banno H et al (2008) Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 38:964–971PubMedCrossRef

26.

Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833–838PubMedCrossRef

27.

Savci S, Inal-Ince D, Arikan H et al (2005) Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil 27:1365–1371PubMedCrossRef

28.

Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707–710PubMedCrossRef

29.

Rascol O (2009) “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 72:S51–S58PubMedCrossRef

30.

de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:456–460PubMedCrossRef

31.

Pascuzzi RM, Shefner J, Chappell AS et al (2010) A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:266–271PubMedCrossRef

32.

Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045–1053PubMedCrossRef

33.

Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283–294PubMedCrossRef

Title: Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy
Authors: Atsushi Hashizume
Masahisa Katsuno
Haruhiko Banno
Keisuke Suzuki
Noriaki Suga
Fumiaki Tanaka
Gen Sobue
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 4/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-011-6251-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Wildervanck’s syndrome and mirror movements: a congenital disorder of axon migration?

Recurrent hypothermia with hyperhidrosis in two siblings: familial Shapiro syndrome variant

The C9ORF72 syndrome: implications for clinical practice

Muscle biopsy

Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants

Social-emotional dysfunction after isolated right anterior insular infarction